ArticleCurrent pharmaceutical design2026
Multidimensional Data-Driven Mechanistic Insights into Anle Tablets for Depression Treatment through Molecular Docking and Dynamics.
Article in Current pharmaceutical design, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDepression is a serious mental health problem, leading to low mood, loss of interest, and even extreme behaviors. Anle tablets are commonly used in the clinical treatment of depression; however, their mechanism of action is still unclear.
methodsComponents and targets of Anle tablets were identified using Traditional Chinese Medicine Systems Pharmacology Database (TCMSP), PubChem, and SwissTargetPrediction. Depression-related targets were searched from the Genecards, Online Mendelian Inheritance in Man (OMIM), and the Therapeutic Target Database (TTD). A network diagram was constructed to screen the core components. We conducted enrichment analysis to demonstrate the underlying molecular mechanisms. Feature targets were identified utilizing the Gene Expression Omnibus (GEO), machine learning, and a nomogram. We subsequently performed preliminary validation using molecular docking and another GEO dataset. Finally, we performed a dynamic analysis of drug-target protein binding using molecular dynamics simulations.
resultsIGF1R, HSD11B1, GABRA1, and OPRK1 were screened as the feature targets. The core components were screened, such as 3,22-Dihydroxy-11-oxo-delta(12)-oleanene-27-alpha-methoxycarbonyl-29-oic acid (MOL004905), (+)-Anomalin, and 7-Acetoxy-2-methylisoflavone. The primary mechanisms of action were associated with synaptic function and neurotransmitter transmission. The drug component MOL004905 and the target protein HSD11B1 emerged as the optimal docking pair. Their binding sites and the forces of interaction between them revealed strong stability. DISCUSSION: This study employed a multifaceted approach, integrating network pharmacology, bioinformatics, molecular docking, and molecular dynamics simulations, to analyze the components, targets, and mechanisms of Anle tablets in the treatment of depression. It also simulated the combination of drug molecules and target proteins and conducted a comprehensive evaluation.
conclusionAnle tablets may exert their therapeutic effects by targeting feature targets through their core active components, thereby modulating synaptic function and neurotransmitter transmission.
Indexed as
Identifiers
41820321What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.